Human embryonic stem cell-derived mesenchymal stromal cell transplantation in a rat hind limb injury model

References

• Javazon EH, Beggs KJ, Flake AW. Mesenchymal stem cells: paradoxes of passaging. Exp Hematol 2004;32:414–25.
   PubMed Web of Science ®Google Scholar
• Friedenstein AJ, Petrakova KV, Kurolesova AI, Frolova GP. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation 1968;6:230–47.
   PubMed Web of Science ®Google Scholar
• Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, . Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143–7.
   PubMed Web of Science ®Google Scholar
• Porada CD, Zanjani ED, Almeida-Porad G. Adult mesenchymal stem cells: a pluripotent population with multiple applications. Curr Stem Cell Res Ther 2006;1:365–9.
   PubMedGoogle Scholar
• Giordano A, Galderisi U, Marino IR. From the laboratory bench to the patient's bedside: an update on clinical trials with mesenchymal stem cells. J Cell Physiol 2007;211:27–35.
   PubMed Web of Science ®Google Scholar
• Picinich SC, Mishra PJ, Mishra PJ, Glod J, Banerjee D. The therapeutic potential of mesenchymal stem cells. Cell- and tissue-based therapy. Expert Opin Biol Ther 2007;7:965–73.
   PubMed Web of Science ®Google Scholar
• Caplan AI. Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J Cell Physiol 2007;213:341–7.
   PubMed Web of Science ®Google Scholar
• Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, . Minimal criteria for defining multi-potent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006;8:315–7.
   PubMed Web of Science ®Google Scholar
• Trivedi P, Hematti P. Simultaneous generation of CD34+ primitive hematopoietic cells and CD73+ mesenchymal stem cells from human embryonic stem cells cocultured with murine OP9 stromal cells. Exp Hematol 2007;35:146–54.
   PubMed Web of Science ®Google Scholar
• Trivedi P, Hematti P. Derivation and immunological characterization of mesenchymal stromal cells from human embryonic stem cells. Exp Hematol 2008;36:350–9.
   PubMedGoogle Scholar
• Barberi T, Bradbury M, Dincer Z, Panagiotakos G, Socci ND, Studer L. Derivation of engraftable skeletal myoblasts from human embryonic stem cells. Nat Med 2007;13:642–8.
   PubMed Web of Science ®Google Scholar
• Hwang NS, Varghese S, Lee HJ, Zhang Z, Ye Z, Bae J, . In vivo commitment and functional tissue regeneration using human embryonic stem cell-derived mesenchymal cells. Proc Natl Acad Sci USA 2008;105:20641–6.
   PubMed Web of Science ®Google Scholar
• Kinnaird T, Stabile E, Burnett MS, Shou M, Lee CW, Barr S, . Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation 2004;109:1543–9.
   PubMed Web of Science ®Google Scholar
• Koponen JK, Kekarainen T, Heinonen S, Laitinen A, Nystedt J, Laine J, . Umbilical cord blood-derived progenitor cells enhance muscle regeneration in mouse hindlimb ischemia model. Mol Ther 2007;12:2172–7.
   Google Scholar
• Kim SW, Han H, Chae GT, Lee SH, Bo S, Yoon JH, . Successful stem cell therapy using umbilical cord blood-derived multipotent stem cells for Buerger's disease and ischemic limb disease animal model. Stem Cells 2006;24:1620–6.
   PubMed Web of Science ®Google Scholar
• Ishikane S, Ohnishi S, Yamahara K, Sada M, Harada K, Mishima K, . Allogeneic injection of fetal membrane-derived mesenchymal stem cells induces therapeutic angiogenesis in a rat model of hind limb ischemia. Stem Cells 2008;26:2625–33.
   PubMed Web of Science ®Google Scholar
• Iwase T, Nagaya N, Fujii T, Itoh T, Murakami S, Matsumoto T, . Comparison of angiogenic potency between mesenchymal stem cells and mononuclear cells in a rat model of hindlimb ischemia. Cardiovasc Res 2005;66:543–51.
   PubMed Web of Science ®Google Scholar
• Muller-Ehmsen J, Krausgrill B, Burst V, Schenk K, Neisen UC, Fries JW, . Effective engraftment but poor mid-term persistence of mononuclear and mesenchymal bone marrow cells in acute and chronic rat myocardial infarction. J Mol Cell Cardiol 2006;41:876–84.
   PubMed Web of Science ®Google Scholar
• Zhang H, Song P, Tang Y, Zhang XL, Zhao SH, Wei YJ, . Injection of bone marrow mesenchymal stem cells in the borderline area of infarcted myocardium: heart status and cell distribution. J Thorac Cardiovasc Surg 2007;134:1234–40.
   PubMedGoogle Scholar
• Iop L, Chiavegato A, Callegari A, Bollini S, Piccoli M, Pozzobon M, . Different cardiovascular potential of adult- and fetal-type mesenchymal stem cells in a rat model of heart cryoinjury. Cell Transplant 2008;17:679–94.
   PubMed Web of Science ®Google Scholar
• Feng SW, Lu XL, Liu ZS, Zhang YN, Liu TY, Li JL, . Dynamic distribution of bone marrow-derived mesenchymal stromal cells and change of pathology after infusing into mdx mice. Cytotherapy 2008;10:254–64.
   PubMed Web of Science ®Google Scholar
• Gnecchi M, He H, Noiseux N, Liang OD, Zhang L, Morello F, . Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J 2006;20:661–9.
   PubMed Web of Science ®Google Scholar
• Nagaya N, Kangawa K, Itoh T, Iwase T, Murakami S, Miyahara Y, . Transplantation of mesenchymal stem cells improves cardiac function in a rat model of dilated cardiomyopathy. Circulation 2005;112:1128–35.
   PubMed Web of Science ®Google Scholar
• Egami K, Murohara T, Aoki M, Matsuishi T. Ischemia-induced angiogenesis: role of inflammatory response mediated by P-selectin. J Leukoc Biol 2006;79:971–6.
   PubMed Web of Science ®Google Scholar
• Shireman PK. The chemokine system in arteriogenesis and hind limb ischemia. J Vasc Surg 2007;45(Suppl A):A48–56.
   Google Scholar
• Du YY, Zhou SH, Zhou T, Su H, Pan HW, Du WH, . Immuno-inflammatory regulation effect of mesenchymal stem cell transplantation in a rat model of myocardial infarction. Cytotherapy 2008;10:469–78.
   PubMed Web of Science ®Google Scholar
• Connolly DT, Heuvelman DM, Nelson R, Olander JV, Eppley BL, Delfino JJ, . Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 1989;84:1470–8.
   PubMed Web of Science ®Google Scholar
• Lescaudron L, Peltekian E, Fontaine-Perus J, Paulin D, Zampieri M, Garcia L, . Blood borne macrophages are essential for the triggering of muscle regeneration following muscle transplant. Neuromuscul Disord 1999;9:72–80.
   PubMedGoogle Scholar
• Ballaun C, Weninger W, Uthman A, Weich H, Tschachler E. Human keratinocytes express the three major splice forms of vascular endothelial growth factor. J Invest Dermatol 1995;104:7–10.
   PubMed Web of Science ®Google Scholar
• Pittenger MF, Martin BJ. Mesenchymal stem cells and their potential as cardiac therapeutics. Circ Res 2004;95:9–20.
   PubMed Web of Science ®Google Scholar
• Horwitz E, Dominici M. How do mesenchymal stromal cells exert their therapeutic benefit? Cytotherapy 2008;10:771–4.
   PubMed Web of Science ®Google Scholar
• Rosova I, Dao M, Capoccia B, Link D, Nolta JA. Hypoxic preconditioning results in increased motility and improved therapeutic potential of human mesenchymal stem cells. Stem Cells 2008;26:2173–82.
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, . Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008;371:1579–86.
   PubMed Web of Science ®Google Scholar
• Hematti P. Role of mesenchymal stromal cells in solid organ transplantation. Transplant Rev 2008;22:262–73.
   Google Scholar
• Niemeyer P, Vohrer J, Schmal H, Kasten P, Fellenberg J, Suedkamp N, Mehlhorn AT. Survival of human mesenchymal stromal cells from bone marrow and adipose tissue after xenogenic transplantation in immunocompetent mice. Cytotherapy 2008;10:784–95.
   PubMed Web of Science ®Google Scholar
• Chang C, Niu D, Zhou H, Zhang Y, Li F, Gong F. Mesenchymal stromal cells improve hyperglycemia and insulin deficiency in the diabetic porcine pancreatic microenvironment. Cytotherapy 2008;10:796–805.
   PubMed Web of Science ®Google Scholar
• Tojo T, Ushio-Fukai M, Yamaoka-Tojo M, Ikeda S, Patrushev N, Alexander RW. Role of gp91phox (Nox2)-containing NAD(P)H oxidase in angiogenesis in response to hindlimb ischemia. Circulation 2005;111:2347–55.
   PubMed Web of Science ®Google Scholar
• Hung SC, Pochampally RR, Chen SC, Hsu SC, Prockop DJ. Angiogenic effects of human multipotent stromal cell conditioned medium activate the PI3K-Akt pathway in hypoxic endothelial cells to inhibit apoptosis, increase survival, and stimulate angiogenesis. Stem Cell 2007;25:2363–70.
   PubMed Web of Science ®Google Scholar
• Kasper G, Dankert N, Tuischer J, Hoeft M, Gaber T, Glaeser JD, . Mesenchymal stem cells regulate angiogenesis according to their mechanical environment. Stem Cells 2007;25:903–10.
   PubMed Web of Science ®Google Scholar
• Rissanen TT, Markkanen JE, Gruchala M, Heikura T, Puranen A, Kettunen MI, . VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses. Circ Res 2003;92:1098–106.
   PubMed Web of Science ®Google Scholar
• Milkiewicz M, Hudlicka O, Shiner R, Egginton S, Brown MD. Vascular endothelial growth factor mRNA and protein do not change in parallel during non-inflammatory skeletal muscle ischaemia in rat. J Physiol 2006;577:671–8.
   PubMedGoogle Scholar
• D'Angelo G, Struman I, Martial J, Weiner RI. Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kDa N-terminal fragment of prolactin. Proc Natl Acad Sci USA 1995;92:6374–8.
   PubMed Web of Science ®Google Scholar